Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| October 11, 2018 | Ordinary Shares (25p) | £14.7475 | 1,566 shares | London Stock Exchange |
Note: Total volume is the aggregate of three separate transactions reported in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by insiders via dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share transactions.
Investor Verification Points
- Transaction Nature: Verify that all reported share acquisitions were executed through dividend reinvestment plans, not open market purchases.
- Insider Identities: Confirm the roles of the transacting parties: Mrs. V A Whyte (Company Secretary), Mr. I W Whyte (PCA of Company Secretary), and Ms. D Connor (PCA of President, Global Vaccines).
- Pricing Consistency: Note that all three transactions occurred at the identical price of £14.7475 on the same date.
- Scope Limitation: Acknowledge that this filing provides no data on GSK's overall financial performance for the period.